FDA recall, , High risk
Medical Action Industries Medline Angiographic Manifold Packs
Cardiovascular procedure kits contain manifolds that may have particulate within the fluid path, which could become lodged in blood vessels.
Summary by Recall Canary from the FDA notice
What happened
Medical Action Industries, Inc., located in Arden, North Carolina, recalled Pack Angiography NCMC 3/Cs BANNER, REF: NCAG62I, containing Medline Namic Angiographic Star Off Handle Manifolds. The kits contain manifolds that may have particulate within the fluid path, which has the potential to be introduced into blood circulation and become lodged within blood vessels.
The recall began May 13, 2026, and was added to the FDA's Enforcement Report on July 30, 2026. The affected product was distributed in Arizona and Colorado.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medical device recalls:
- A device recall doesn't always mean you must stop using it: it may need to be checked, adjusted or fixed.
- Talk to your health care provider before you stop using it.
Is yours affected?
Match the UDI-DI and lot code listed under your product.
A UDI-DI is the device identifier printed with the barcode on the device label.
Pack Angiography NCMC 3/Cs Banner, REF: NCAG62I, containing Medline Namic Angiographic Star Off Handle Manifolds
- UDI-DI
- 20809160490416
- Lot code
- 342513
- 336758
- 338977
Recall details
- Company began the recall
- Company
- Medical Action Industries, Inc. 306Arden, North Carolina
- Hazard
- Foreign object
- Risk
High risk
There is a reasonable chance that using it could cause serious health problems or death.
FDA Class I recall · How risk is rated
- Event ID
- 99337
- Recall number
- Z-2792-2026
All recalls from Medical Action Industries, Inc. 306
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
Listed on Recall Canary
In FDA's weekly enforcement report
Summary updated
